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Introduction: Acute portomesenteric vein thrombosis is an uncommon but serious condition with potential
sequelae, such as small-bowel gangrene and end-stage hepatic failure. It is known to be caused by various
pro-thrombotic states, including hyperhomocysteinemia. We describe what is, to the best of our knowledge,
the first reported case of concomitant thrombosis of portal, superior mesenteric and splenic veins due to
hyperhomocysteinemia secondary to pernicious anemia and no other risk factors.
Case presentation: A 60-year-old Indian man presented with epigastric pain, diarrhea and vomiting. An abdominal
imaging scan showed that he had concomitant pernicious anemia and concomitant portal, superior mesenteric and
splenic vein thrombosis. A work-up for the patient’s hypercoagulable state revealed hyperhomocysteinemia, an
undetectable vitamin B12 level and pernicious anemia with no other thrombophilic state. He developed infarction
with perforation of the small bowel and subsequent septic shock with multi-organ dysfunction syndrome, and he
ultimately died due to progressive hepatic failure.
Conclusion: This report demonstrates that pernicious anemia, on its own, can lead to hyperhomocysteinemia
significant enough to lead to lethal multiple splanchnic vein thrombosis. Our case also underscores the need to
(1) consider portomesenteric thrombosis in the differential diagnosis of epigastric abdominal pain, (2) perform a
complete thrombotic work-up to elucidate metabolic abnormalities that could be contributing to a pro-thrombotic
state and (3) initiate aggressive measures, including early consideration of multi-visceral transplantation, in order to
avoid decompensation and a significant adverse outcome.
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Acute thrombosis of the splanchnic venous circulation
is a condition that, albeit rare in the general popula-
tion, is of vital importance to the clinician, given its life-
threatening sequelae, which include mesenteric infarction
and progressive liver failure [1]. A variety of etiologies
have been shown to cause portal vein thrombosis, such as
cirrhosis, infection of the gastrointestinal tract, malignan-
cies and a variety of hypercoagulable states, including gen-
etic deficiencies in coagulation factors as well as acquired
thrombophilias, such as anti-phospholipid syndrome and* Correspondence: nissatfirdous99@gmail.com
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article, unless otherwise stated.myeloproliferative disease [2]. A high index of suspicion
and thorough evaluation are warranted to diagnose porto-
mesenteric infarction in patients with abdominal pain. In
addition, a thorough work-up needs to be done in order
to elucidate the etiology, especially underlying systemic ill-
ness, in those patients diagnosed with portal vein throm-
bosis. We present what is, to the best of our knowledge,
the first reported case of concomitant thrombosis of the
portal vein, superior mesenteric vein and splenic vein in a
patient with hyperhomocysteinemia secondary to vitamin
B12 deficiency caused by pernicious anemia.
Case presentation
A 60-year-old Indian man presented to our institution
with complaints of generalized epigastric abdominal
pain of moderate intensity for the previous 10 days, withtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 2 Longitudinal computed tomography scan of the
patient’s abdomen with contrast enhancement taken in the
axis of the portal vein showing extensive thrombosis involving
the superior mesenteric, splenic and portal veins.
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His past medical history was significant for anemia that
required blood transfusions on two separate occasions,
but it was otherwise unremarkable. He had arrived in our
area from India two weeks prior to presentation. A pre-
sumptive diagnosis of acute gastroenteritis was made, and
the patient was started on intravenous fluids and admitted
to the medical ward.
Ultrasonography, computed tomography (CT) and mag-
netic resonance imaging scans of the patient’s abdomen
revealed thrombosis of the portal vein, splenic vein and
superior mesenteric vein, along with a hypodense region
in the liver suggestive of infarction and edematous bowel
loops with fat-stranding indicative of mesenteric ische-
mia (Figures 1 and 2). A preliminary blood work-up
revealed macrocytic anemia with 8.7g/dL hemoglobin and
137.1fL mean corpuscular volume. A peripheral blood
smear showed numerous macrocytes, macro-ovalocytes
and hypersegmented neutrophils indicative of megalo-
blastic anemia. His serum folate and red blood cell folate
levels were normal, but his serum vitamin B12 levels were
severely low at <44pmol/L. An additional work-up showed
a positive 1:80 titer for anti–parietal cell antibody and a
markedly positive anti–intrinsic factor antibody level
of 131U, thus establishing the diagnosis of pernicious
anemia. An extensive coagulation work-up showed a
raised prothrombin time (13.3 seconds), an elevated acti-
vated partial thromboplastin time (43.4 seconds) and a
high international normalized ratio (1.3). It also revealed a
normal platelet count, normal protein C and protein S
levels, and normal anti–thrombin III function, as well as a
negative result for lupus anti-coagulant.
Genetic testing for factor V Leiden mutation and JAK2
gene mutation was negative. Immunoglobulin G (IgG) and
IgM assays for anti-cardiolipin and anti-β2-glycoproteinFigure 1 Axial computed tomography scan of the patient’s
abdomen with contrast enhancement showing portal vein
thrombosis causing complete occlusion of the lumen of the
portal vein.antibodies were below diagnostic values, as were anti-
nuclear antibody tests. However, the patient’s serum
homocysteine levels were markedly high at 70μmol/L
(normal 4μmol/L to 12μmol/L). The results of a test for
the methyltetrahydrofolate reductase (MTHFR) gene was
negative for any remarkable polymorphisms, including the
C677T mutation. A genetic test result for factor II muta-
tion was also negative.
The patient was admitted to the medical ward and
started on anti-coagulation therapy with warfarin and low-
molecular-weight heparin, as well as parenteral vitamin B12
therapy, after his vein thromboses were deemed surgically
incorrigible. During his hospital stay, he developed pro-
gressive ascites that required periodic drainage. On day 20
of admission, the ascitic fluid drainage turned turbid and a
CT scan showed mesenteric perforation (Figure 3). An
emergent laparotomy revealed mesenteric gangrene with
perforation, and a bowel resection with ileostomy and
mucus fistula creation was performed. The patient’s recov-
ery was complicated by Bacteroides ovatus bacteremia and
Klebsiella pneumoniae sepsis, which resulted in septic
shock and multi-organ dysfunction syndrome necessi-
tating intensive care. He eventually developed pro-
gressively rising bilirubin and falling albumin levels as
Figure 3 Emergent axial computed tomography scan of the
abdomen with contrast enhancement showing extravasation
of contrast from the proximal small bowel, indicating
bowel perforation.
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tive of end-stage hepatic failure. Despite aggressive
anti-coagulation therapy being administered continu-
ously throughout the patient’s admission, and in spite
of his vitamin B12 and homocysteine levels turning nor-
mal, his thromboses did not resolve. This resulted in
splenic infarction as well as progressive liver failure
with severe hepatic encephalopathy. The patient even-
tually died due to hepatic failure three months into his
hospital stay.
Discussion
Hyperhomocysteinemia is a consequence of vitamin B12
deficiency, because vitamin B12 is required as a cofactor
for the enzyme MTHFR, which remethylates homocyst-
eine to form methionine [3]. Hyperhomocysteinemia has
been well-documented to increase the risk of arterial
thrombotic events, including myocardial infarction [4],
stroke [5] and peripheral arterial disease [6]. Data con-
cerning venous thrombosis also point to an increased
risk for hyperhomocysteinemia [3,7-9]. In one case–
control study, researchers found an increased risk for ven-
ous thromboembolism associated with reduced vitamin
B12, together with increased methylmalonic acid levels, in
the presence of hyperhomocysteinemia [10]. However, the
investigators in the cited studies recruited mostly patients
with deep vein thrombosis and did not include patients
with thrombosis of the splanchnic vasculature.Patients with portomesenteric vein thrombosis and
hyperhomocysteinemia have scarcely been reported.
Landman et al. reported hyperhomocysteinemia in 12
(28%) of 43 patients with portomesenteric vein thrombosis
and concomitant inflammatory bowel disease who were
screened for pro-thrombotic conditions [11]. A case series
reported by Mushtak et al., a group of clinicians at our
institution, included a patient with concomitant portal,
mesenteric and splenic vein thrombosis associated with
hyperhomocysteinemia and vitamin B12 deficiency. How-
ever, that patient tested negative for anti–intrinsic factor
and anti–parietal cell antibodies, and his vitamin B12 defi-
ciency was attributed to his long-term vegan diet [12].
The other two patients in their case series also presented
with venous thrombosis, hyperhomocysteinemia and vita-
min B12 deficiency.
The C677T mutation of the MTHFR gene has been re-
ported in a patient with pernicious anemia and portome-
senteric thrombosis [13]. Our patient, however, tested
negative for the same mutation. Kanbay et al. reported a
case of a patient with elevated liver enzymes, portal vein
thrombosis, vitamin B12 deficiency and elevated homo-
cysteine levels; however, they did not report a cause of
the vitamin B12 deficiency [14]. Tan et al. reported a case
of portal vein thrombosis secondary to hyperhomocys-
teinemia that led to bowel gangrene, all of which were
corrected with folate and vitamin B6 supplementation
[15]. Other case reports associating portomesenteric vein
thrombosis with hyperhomocysteinemia include comorbid
folate deficiency [16], factor V Leiden mutation [17], latent
essential thrombocythemia [18] and the factor II
G20210A mutation [19], with the latter being a relatively
common thrombophilia in Caucasian patients but very
rare in Asian populations, to which our patient belonged.
Our report is unique in that our patient had none of these
additional risk factors.
In all of the aforementioned reports of portomesen-
teric vein thrombosis with vitamin B12 deficiency, anti-
coagulation with concomitant correction of the nutri-
tional deficiency was undertaken as early as possible, but
with varied success. Thus, no clear recommendation was
made in those reports regarding the ideal therapy and
treatment endpoints for such patients with portal throm-
bosis secondary to underlying systemic disease.
Our case presented significant management challenges
because the three major veins comprising the portal circu-
lation were all acutely thrombosed and deemed surgically
incorrigible. Anti-coagulation therapy did not prevent
progression to bowel gangrene, which increases mortality
to 20% to 50% [20], and ultimately to liver failure. Vitamin
B12 supplementation was effective in restoring normal
vitamin B12 and homocysteine levels, but this did not
translate to clinical improvement. Anti-coagulation ther-
apy with low-molecular-weight heparin and warfarin is
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thrombosis, with a six-month recanalization rate of up to
50% and a complete failure rate of 10% [2]. If this treat-
ment fails, however, injection of thrombolytic agents into
the portal vasculature is an option. Recanalization rates
are at best modest, and the high rate of complications calls
into question the prudence of implementing this therapy
[21]. Surgical thrombectomy has been reported, but it car-
ries a high rate of adverse outcomes and is hence not cur-
rently recommended. Vascular reconstruction by surgical
shunting is an option [1], but it requires patency of the
splenic and superior mesenteric veins and hence was not
suitable for our patient. Furthermore, this option has been
successful only in patients with chronic portal thrombosis.
A liver transplant would not have been a viable option for
our patient, as the extensive thrombosis of the splanchnic
veins would have caused rapid graft failure [22].
The only definitive cure for our patient’s condition would
have been multi-visceral transplantation. This would have
involved contiguous transplantation of the liver and the
small bowel, described previously by Nour et al. [22]. The
hepatoenteric graft would have been harvested en bloc
along with the patent splanchnic veins of the donor, and
hence would have ensured viability. The patient would
have been placed on total parenteral nutrition in the post-
operative period until enteral nutrition was adequate [22].
Unfortunately, multi-visceral transplantation was not only
unavailable but also infeasible in the face of acute decom-
pensation of the patient’s clinical condition and superim-
posed sepsis.
Conclusion
To the best of our knowledge, this is the first reported
case of concomitant thrombosis of the portal, superior
mesenteric and splenic veins with hyperhomocysteine-
mia secondary to pernicious anemia and no other risk
factors. Prompt and sustained anti-coagulation with vita-
min B12, together with homocysteine normalization, did
not prevent progression to bowel gangrene and liver fail-
ure. The dearth of evidence regarding alternatives to
anti-coagulation, along with the extensive multi-vessel
thrombosis in our patient, limited the treatment options
that could be offered. This report highlights the fact that
pernicious anemia by itself can lead to hyperhomocys-
teinemia significant enough to lead to lethal multiple
abdominal vein thrombosis. It underscores the need to
(1) consider portomesenteric thrombosis in the differen-
tial diagnosis of epigastric abdominal pain, (2) perform
a complete thrombotic work-up to elucidate metabolic
abnormalities that could be contributing to a pro-
thrombotic state and (3) initiate aggressive measures,
including the early consideration of multi-visceral trans-
plantation, in order to avoid decompensation and a signifi-
cant adverse outcome.Consent
Written informed consent was obtained from the patient’s
next of kin for publication of this case report and any ac-
companying images. A copy of the written consent is avail-
able for review by the Editor-in-Chief of this journal.
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